Dec 03, 2018
|
Phase 1 Expansion Cohort Oral Presentations for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, in Relapsed/Refractory Acute Myeloid Leukemia Presented at 60th ASH Annual Meeting
|
|
Nov 29, 2018
|
MacroGenics and Zai Lab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Margetuximab, MGD013 and TRIDENT™ Molecule in Greater China
|
|
Nov 27, 2018
|
MacroGenics Announces Participation in Three Investor Conferences
|
|
Nov 14, 2018
|
MacroGenics Announces Poster Presentation on Preclinical PD-L1 x CD137 DART® Program at the EORTC-NCI-AACR Symposium in Dublin
|
|
Nov 09, 2018
|
MacroGenics Reports Presentation of Clinical Data at 33rd Annual SITC Meeting
|
|
Nov 07, 2018
|
MacroGenics Provides Update on Corporate Progress and 3rd Quarter 2018 Financial Results
|
|
Oct 31, 2018
|
MacroGenics Announces Date of Third Quarter 2018 Financial Results Conference Call
|
|
Oct 22, 2018
|
MacroGenics Announces Participation in Three Investor Conferences
|
|
Sep 26, 2018
|
MacroGenics Announces Participation in Two Upcoming Investor Conferences
|
|
Aug 30, 2018
|
MacroGenics Announces Participation in Three Upcoming Investor Conferences
|
|
Aug 09, 2018
|
MacroGenics to Present at Wedbush PacGrow Healthcare Conference
|
|
Aug 07, 2018
|
MacroGenics Provides Update on Corporate Progress and 2nd Quarter 2018 Financial Results
|
|
Jul 30, 2018
|
MacroGenics Announces Date of Second Quarter 2018 Financial Results Conference Call
|
|
Jun 05, 2018
|
MacroGenics to Present at Jefferies Global Healthcare Conference
|
|
May 07, 2018
|
MacroGenics to Present at Deutsche Bank Health Care Conference
|
|
May 07, 2018
|
MacroGenics Provides Update on Corporate Progress and 1st Quarter 2018 Financial Results
|
|
Apr 30, 2018
|
MacroGenics Announces Date of First Quarter 2018 Financial Results Conference Call
|
|
Apr 02, 2018
|
MacroGenics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
|
|
Mar 28, 2018
|
MacroGenics Announces Pricing of Public Offering of Common Stock
|
|
Mar 26, 2018
|
MacroGenics Announces Proposed Public Offering of Common Stock
|
|
Mar 09, 2018
|
MacroGenics to Present at Cowen Health Care Conference
|
|
Feb 27, 2018
|
MacroGenics Provides Update on Corporate Progress and 2017 Financial Results
|
|
Feb 14, 2018
|
MacroGenics Announces Date of Fourth Quarter and Full Year 2017 Financial Results Conference Call
|
|
Feb 06, 2018
|
MacroGenics to Participate in Two Upcoming Investor Conferences
|
|
Jan 23, 2018
|
MacroGenics Announces Continuation of SOPHIA Study of Margetuximab Based on Completion of Interim Futility Analysis
|
|